[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pulmatrix Inc (PULM)

Pulmatrix Inc (PULM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,565
  • Shares Outstanding, K 3,652
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,160 K
  • EBIT $ -5 M
  • EBITDA $ -5 M
  • 60-Month Beta 1.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.52

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2000 +4.17%
on 04/17/26
1.4600 -14.38%
on 04/21/26
unch (unch)
since 04/15/26
3-Month
1.1600 +7.76%
on 04/13/26
3.4000 -63.24%
on 02/25/26
-1.1850 (-48.67%)
since 02/13/26
52-Week
1.1600 +7.76%
on 04/13/26
9.3700 -86.66%
on 05/29/25
-5.2710 (-80.83%)
since 05/15/25

Most Recent Stories

More News
Pulmatrix Announces First Quarter 2026 Financial Results

Announced merger agreement with Eos SENOLYTIX in March

PULM : 1.2500 (-1.57%)
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger

Series B Preferred Stock investment made in Pulmatrix with a conversion price of $2.20 is a part of the ongoing merger process

PULM : 1.2500 (-1.57%)
PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior...

PULM : 1.2500 (-1.57%)
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

FRAMINGHAM, Mass. and HOUSTON , March 26, 2026 /PRNewswire/ --  Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix") and Eos SENOLYTIX, Inc. ("Eos"), a biotechnology company developing novel gerotherapeutic...

PULM : 1.2500 (-1.57%)
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

Cullgen had been seeking approval for a merger with Pulmatrix from the China Securities Regulatory Commission and on February 28, 2026, notified Pulmatrix that Cullgen was terminating the Merger Agreement...

PULM : 1.2500 (-1.57%)
Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

Plans to License or Monetize our Migraine and Inhalation Assets Continue

PULM : 1.2500 (-1.57%)
Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

Pulmatrix continues to support Cullgen in seeking approval for their merger from the China Securities Regulatory Commission

PULM : 1.2500 (-1.57%)
Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small- or large-molecule...

PULM : 1.2500 (-1.57%)
Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

Proposed merger anticipated to close in 2025

PULM : 1.2500 (-1.57%)
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...

PULM : 1.2500 (-1.57%)

Business Summary

Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease...

See More

Key Turning Points

3rd Resistance Point 1.2852
2nd Resistance Point 1.2781
1st Resistance Point 1.2641
Last Price 1.2500
1st Support Level 1.2430
2nd Support Level 1.2359
3rd Support Level 1.2219

See More

52-Week High 9.3700
Fibonacci 61.8% 6.2338
Fibonacci 50% 5.2650
Fibonacci 38.2% 4.2962
Last Price 1.2500
52-Week Low 1.1600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.